Fantastic news for your day. Rates of COVID-19 cases, patient numbers, hospital admissions, AND deaths are now ALL falling in England. Week-on-week infections have now dropped for 18 days straight AND cases are falling in ALL age groups.
Read more here: ft.com/content/e11add…. This article also gives a great analysis on the rest of Europe and shows in well-vaccinated countries like the Netherlands and the UK, while cases have climbed close to past peaks, hospitalizations AND deaths remain at LOWER levels.
Keep in mind, this is with no new measures currently implemented in England. Vaccinations, boosters, and acquired/hybrid immunity are doing the heavy lifting here as they should!💪💥
“Breakthrough” infections DO NOT mean vaccines don’t work. Remember, they are preventives NOT cures. One can still contract COVID once vaccinated. As long as that vaccine is preventing you from facing severe disease and worse, it IS working and doing what it was designed to do.🧵
Regarding the concerns about waning immunity. Please remember, this is likely referring to infection. NOT effectiveness against symptomatic infection, NOT effectiveness against severe illness. While neutralizing antibodies decrease over time (as they ARE supposed to) protective
immunity provided by memory B-cells and T-cells is STILL present. Remember: Immunological memory consists of antibodies, memory B-cells, memory CD8+ T-cells, and memory CD4+ T-cells. These responses give us enduring protection even against newly emerging SARS-CoV-2 variants.
It is a GREAT morning when you find studies that can help put to rest concerns about AY.4.2, B.1.617.2+E484K, AY.1, AY.2 (or rather “Delta-Plus” in general) Lambda, B.1.1.519, A.30, Mu and so much more.
When I say the vaccines can handle variants I mean it. Working on a thread.
A recent study out Denmark shows a sublineage of the Delta variant, AY.4.2, was NOT more resistant to neutralization relative to other circulating Delta lineages or sublineages AND showed ONLY a MODEST 2.3-fold reduction in neutralization.
Let’s talk about that and more!
AY.4.2 recently accounted for an increase proportion of Delta cases in United Kingdom (UK), Romania, Poland, and Denmark. Here, researchers evaluated the sensitivity of AY.4.2 to neutralization by sera from Pfizer recipients. AY.4.2 was NOT more resistant to neutralization
Marten Microbiology is a new panel series (along with Q&A sessions) I will be running at conventions I attend. Let’s talk about viruses, vaccines, and so much more! Stay tuned here for announcements and be sure to check convention programming details!
First up will be @BewhiskeredCon this Friday November 12th, 2021 at 7:30pm EST. I will be attending as a GoH! Registration is already sold out but don’t worry, it will be recorded and streamed!
If you see the claim that there are currently 14X more COVID-19 patients in UK hospitals than this time last year, that is blatant MISINFORMATION at best. There were 14,546 hospitalized COVID-19 patients a year ago (November 8, 2020), and 9,160 today.
You can easily go on the UK Coronavirus Dashboard. The information is right at your fingertips. coronavirus.data.gov.uk/details/health…. Misinformation or just downright blatant lies doesn’t help promote vaccine uptake, if anything it promotes hesitancy.
What is important to know, and can be seen when comparing last year to where we are currently is that the vaccines are highly effective in preventing severe disease, hospitalization, and death due to COVID-19 even in the face of the Delta variant.
Just a friendly reminder. Despite what you might hear, there has yet to be a variant that isn’t susceptible to the vaccines.
Why are variants unlikely to FULLY evade vaccine-induced immunity?
•Vaccines are polyclonal
•CD8+ T-cells covering 52 epitopes across the spike protein
•CD4+ T-cells covering 23 epitopes across the spike protein
You can learn about epitopes here: news-medical.net/life-sciences/…
Regarding the concerns about waning immunity. Please remember, this is likely referring to infection. Not effectiveness against symptomatic infection, not effectiveness against severe illness. See: bmj.com/content/374/bm…
FANTASTIC news for your Friday! Phase 2/3 results of PAXLOVID, Pfizer’s COVID-19 oral antiviral shows the risk of hospitalization or death is REDUCED by NEARLY 90% in high-risk adults with COVID-19 when taken within three days of experiencing symptoms.
Let’s talk about that! 🧵
IMPORTANT NOTE: this protease inhibitor was originally developed for SARS-CoV in 2003 and has been repurposed! So first, let’s discuss the results. The scheduled interim analysis showed an 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared
to placebo in patients treated within three days of symptom onset (primary endpoint); 0.8% of patients who received PAXLOVID™ were hospitalized through Day 28 following randomization (3/389 hospitalized with NO deaths), compared to 7.0% of patients who received placebo and